CMS Offers Two Paths To “Coverage With Evidence” In Revised Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
The agency aims to clarify its rationale and solidify the legal basis for requiring data collection as a condition of national Medicare coverage in guidelines issued July 12.
You may also be interested in...
Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.
Quality Of Biomarkers Questioned Again; Lancet Report Calls For Better Evidence
As personalized medicine shifts from theory to practice, concerns are mounting about whether the evidence behind many biomarkers is sufficient to make pharmacogenomic testing worthwhile – suggesting sponsors should pay careful attention to providing evidence to support use of companion diagnostics.
Costs Are “Valid” Selection Factor In Medicare “Coverage With Evidence Development” Option – NIH Bioethicists
Medicare CED policy does not compromise ethical standards for medical research, they conclude in JAMA commentary.